MedPath

GE MEDICAL SYSTEMS

🇫🇷France
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

163

Active:4
Completed:101

Trial Phases

5 Phases

Phase 1:12
Phase 2:10
Phase 3:18
+2 more phases

Drug Approvals

4

FDA:4

Drug Approvals

CLARISCAN

Approval Date
Jan 11, 2024
FDA

CLARISCAN

Approval Date
Jan 11, 2024
FDA

Omnipaque

Approval Date
May 5, 2023
FDA

Omnipaque

Approval Date
Apr 25, 2023
FDA

Clinical Trials

Distribution across different clinical trial phases (119 trials with phase data)• Click on a phase to view related trials

Not Applicable
61 (51.3%)
Phase 3
18 (15.1%)
Phase 4
18 (15.1%)
Phase 1
12 (10.1%)
Phase 2
10 (8.4%)

Point of Care Lung Ultrasound Examination in Patients With Shortness of Breath

Not Applicable
Not yet recruiting
Conditions
Lung Disease
Lung Ultrasound
First Posted Date
2025-07-01
Last Posted Date
2025-07-01
Lead Sponsor
GE Healthcare
Target Recruit Count
150
Registration Number
NCT07046234
Locations
🇺🇸

Yale University School of Medicine, New Haven, Connecticut, United States

🇺🇸

Rush University Medical Center, Chicago, Illinois, United States

🇺🇸

Northwestern University, Evanston, Illinois, United States

NIBP Cuff Comparison Study

Completed
Conditions
Blood Pressure
Blood Pressure Measurement
First Posted Date
2025-06-17
Last Posted Date
2025-07-03
Lead Sponsor
GE Healthcare
Target Recruit Count
32
Registration Number
NCT07024472
Locations
🇫🇮

Metropolia University of Applied Sciencies, Helsinki, Finland

CARESCAPE Monitoring Systems ME Study

Not Applicable
Conditions
Surgery, Intensive Care
First Posted Date
2025-06-17
Last Posted Date
2025-06-17
Lead Sponsor
GE Healthcare
Target Recruit Count
80
Registration Number
NCT07024459
Locations
🇫🇮

Helsinki University Hospital, Espoo, Uusimaa, Finland

Maternal Fetal Device Performance Twins

Not Applicable
Recruiting
Conditions
Pregnancy
First Posted Date
2025-02-19
Last Posted Date
2025-02-19
Lead Sponsor
GE Healthcare
Target Recruit Count
15
Registration Number
NCT06835647
Locations
🇺🇸

Element Materials Technology, Louisville, Colorado, United States

Next Generation CT System

Recruiting
Conditions
Computed Tomography
First Posted Date
2025-01-10
Last Posted Date
2025-05-06
Lead Sponsor
GE Healthcare
Target Recruit Count
100
Registration Number
NCT06769594
Locations
🇺🇸

University of Wisconsin, Madison, Madison, Wisconsin, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 32
  • Next

News

Bayer Submits Low-Dose MRI Contrast Agent Gadoquatrane for Global Regulatory Approval

Bayer has submitted marketing authorization applications for gadoquatrane, an investigational MRI contrast agent that delivers 60% lower gadolinium dosing compared to standard agents while maintaining diagnostic efficacy.

FDA Expands Optison Ultrasound Enhancing Agent Approval for Pediatric Cardiac Imaging

The FDA has expanded approval for GE HealthCare's Optison, allowing the ultrasound enhancing agent to be used in pediatric patients with suboptimal echocardiograms, following successful Phase IV clinical trials.

GE HealthCare's Aurora SPECT/CT and Clarify DL Receive FDA Clearance, Advancing Nuclear Medicine Imaging

GE HealthCare has received FDA 510(k) clearance for its Aurora nuclear medicine system and Clarify DL, with University Hospitals in Cleveland becoming the first U.S. institution to adopt this technology.

Turing Medical Appoints Kevin King as CEO to Advance Brain Mapping Technology and Depression Treatment

Turing Medical has appointed Kevin King, former CEO of iRhythm Technologies, as its new President and Chief Executive Officer to accelerate the company's expansion in precision brain mapping technology.

FDA Clears J&J's AI-Enhanced Monarch Robot for Improved Lung Cancer Diagnosis

• Johnson & Johnson's Monarch Quest software update received FDA 510(k) clearance, boosting computational power by 260% to improve accuracy in reaching suspicious lung nodules. • The enhanced robotic platform integrates Nvidia's AI technology and GE Healthcare's OEC 3D mobile imaging system to navigate complex patient airways for more precise early-stage lung cancer diagnosis. • This advancement addresses a critical need in lung cancer detection, as nearly half of early-stage lesions occur in peripheral lung areas that are difficult to access with traditional bronchoscopy methods.

GE HealthCare Launches Flyrcado, Revolutionary PET Imaging Agent for Coronary Artery Disease

GE HealthCare has successfully administered the first doses of Flyrcado, an FDA-approved PET imaging agent for coronary artery disease detection, at Houston Methodist Hospital.

AI-Powered Breast Cancer Detection Gains FDA Clearance for Expanded Mammography System Compatibility

SmartMammo Dx, an AI algorithm by DeepHealth, secured FDA clearance for use with GE HealthCare's Senographe Pristina mammography systems.

Polarean Imaging Receives FDA Clearance to Expand MRI Chest Coil Compatibility

Polarean Imaging secured FDA 510k clearance for its MRI chest coil to include GE Healthcare's 3 Tesla MRI scanners, enhancing Xenon-129 nuclei visualization.

GE HealthCare's SIGNA MAGNUS Head-Only MRI System Receives FDA Clearance

GE HealthCare's SIGNA MAGNUS, a 3.0T head-only MRI, has received FDA clearance, offering advanced neuroimaging capabilities for clinical and research use.

GE HealthCare's Signa Magnus Head-Only MRI Scanner Receives FDA Clearance

GE HealthCare's Signa Magnus, a head-only MRI scanner, has received 510(k) clearance from the U.S. Food and Drug Administration, facilitating its market entry.

© Copyright 2025. All Rights Reserved by MedPath